Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many advance-stage epithelial cancers. These agents have the superior ability to target cancers cells and better safety profile compared to conventional chemotherapies. However, cu...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | Dermatology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2014/734249 |